| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
BridgeBio Oncology Therapeutics, Inc.
13D/A
BBOT · 107924102
|
22.3% |
7/6/2026
Event 7/1/2026
|
||||
| Bihua Chen | 22.3% | |||||
| Cormorant Private Healthcare Fund III, LP | 6.1% | |||||
| Cormorant Private Healthcare GP III, LLC | 6.1% | |||||
| Cormorant Private Healthcare Fund V, LP | 6.3% | |||||
| Cormorant Private Healthcare GP V, LLC | 6.3% | |||||
| Cormorant Global Healthcare Master Fund, LP | 7.6% | |||||
| Cormorant Global Healthcare GP, LLC | 7.6% | |||||
| Helix Holdings II LLC | 0% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
MoonLake Immunotherapeutics
13G/A
MLTX · 61559X104
|
3.1% |
10/1/2025
Event 9/30/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.